Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Recruiting
N/A
Interventional Study
Stage III Non-small-cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Radiotherapy Side Effect
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 151 (estimated)
- Sponsor
- Danish Lung Cancer Group · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting s…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically or cytological confirmed locally advanced, inoperable NSCLC.
* Age ≥18 years.
* Signed informed consent.
* Performance status 0-2.
* Able to comply with study and follow-up procedures.
* Fertile women must have a negative pregnancy test. Fertile men and women mu…
Contacts